Defibrotide (Defitelio®)

Assessment Status Rapid review complete
Drug Defibrotide
Brand Defitelio®
Indication Indicated in adults, children and infants (>1month) for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy
Assessment Process
Rapid review commissioned 12/05/2014
Rapid review completed 10/07/2014
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.